X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Piramal Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA PIRAMAL ENTERPRISES AJANTA PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 25.4 36.6 69.3% View Chart
P/BV x 10.5 3.0 343.5% View Chart
Dividend Yield % 0.6 0.8 71.8%  

Financials

 AJANTA PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
PIRAMAL ENTERPRISES
Mar-17
AJANTA PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs1,7202,095 82.1%   
Low Rs1,1031,025 107.6%   
Sales per share (Unadj.) Rs194.6492.8 39.5%  
Earnings per share (Unadj.) Rs45.272.6 62.3%  
Cash flow per share (Unadj.) Rs50.394.7 53.1%  
Dividends per share (Unadj.) Rs8.0021.00 38.1%  
Dividend yield (eoy) %0.61.3 42.1%  
Book value per share (Unadj.) Rs132.0862.5 15.3%  
Shares outstanding (eoy) m88.77172.56 51.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.33.2 229.1%   
Avg P/E ratio x31.221.5 145.2%  
P/CF ratio (eoy) x28.116.5 170.3%  
Price / Book Value ratio x10.71.8 591.0%  
Dividend payout %17.728.9 61.1%   
Avg Mkt Cap Rs m125,299269,194 46.5%   
No. of employees `000NA4.0 0.0%   
Total wages/salary Rs m2,57017,939 14.3%   
Avg. sales/employee Rs ThNM21,190.3-  
Avg. wages/employee Rs ThNM4,470.1-  
Avg. net profit/employee Rs ThNM3,120.0-  
INCOME DATA
Net Sales Rs m17,27585,037 20.3%  
Other income Rs m1662,338 7.1%   
Total revenues Rs m17,44287,374 20.0%   
Gross profit Rs m5,80734,991 16.6%  
Depreciation Rs m4513,817 11.8%   
Interest Rs m4920,310 0.2%   
Profit before tax Rs m5,47413,202 41.5%   
Minority Interest Rs m01,699 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-100 0.0%   
Tax Rs m1,4602,281 64.0%   
Profit after tax Rs m4,01412,520 32.1%  
Gross profit margin %33.641.1 81.7%  
Effective tax rate %26.717.3 154.3%   
Net profit margin %23.214.7 157.8%  
BALANCE SHEET DATA
Current assets Rs m7,63987,590 8.7%   
Current liabilities Rs m2,715185,578 1.5%   
Net working cap to sales %28.5-115.2 -24.7%  
Current ratio x2.80.5 596.2%  
Inventory Days Days4331 139.3%  
Debtors Days Days7948 165.5%  
Net fixed assets Rs m6,914108,523 6.4%   
Share capital Rs m177345 51.3%   
"Free" reserves Rs m11,442148,481 7.7%   
Net worth Rs m11,721148,826 7.9%   
Long term debt Rs m149144,957 0.1%   
Total assets Rs m14,814482,394 3.1%  
Interest coverage x112.91.7 6,844.9%   
Debt to equity ratio x01.0 1.3%  
Sales to assets ratio x1.20.2 661.5%   
Return on assets %27.46.8 403.0%  
Return on equity %34.28.4 407.1%  
Return on capital %46.512.0 389.3%  
Exports to sales %55.10-   
Imports to sales %6.00-   
Exports (fob) Rs m9,527NA-   
Imports (cif) Rs m1,038NA-   
Fx inflow Rs m10,42215,001 69.5%   
Fx outflow Rs m1,6785,150 32.6%   
Net fx Rs m8,7449,851 88.8%   
CASH FLOW
From Operations Rs m3,264-100,393 -3.3%  
From Investments Rs m-2,093-24,202 8.6%  
From Financial Activity Rs m-1,186135,705 -0.9%  
Net Cashflow Rs m-1511,110 -0.1%  

Share Holding

Indian Promoters % 73.8 52.9 139.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 4.0 38.8%  
FIIs % 7.6 26.6 28.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 16.5 103.0%  
Shareholders   20,968 93,274 22.5%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   GLENMARK PHARMA  FULFORD INDIA  MERCK LTD  BIOCON LTD  UNICHEM LAB  

Compare AJANTA PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Feb 16, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS